Study of the effect of Hydroxychloroquine in addition to standard therapy in COVID-19 patients

INTERVENTION: Intervention1: Hydroxychloroquine sulphate: Hydroxychloroquine sulphate tablets will be given in the dose of 400 mg twice on day 1 and then 400 mg once in a day for 04 days daily to the patients who meets the inclusion criteria Control Intervention1: No drug: Hydroxychloroquine will not be given to control group. These patients will be managed as per standard protocol. CONDITION: Health Condition 1: B972‐ Coronavirus as the cause of diseases classified elsewhere PRIMARY OUTCOME: number of days of hospitalizationTimepoint: discharge SECONDARY OUTCOME: death ; days to normalization of SaO2 ; days to normalization of pulse rate less than 90/min ; number of days of requirement of oxygen ; number of days from admission to ventilator requirement ; number of days on ventilator and occurrence of side effectsTimepoint: death or discharge INCLUSION CRITERIA: a. Patients with oxygen saturation (SPO2) less than 95% b. Respiratory rate is more than 20/min c. Pulse rate more than 90/min d. Imaging evidence of lung infection in the form of Reticulonodular opacities, ground‐glass opacities, consolidation and Acute Respiratory Distress Syndrome (ARDS)